BaiZe Medical (02609.HK) Hong Kong Hot Stock Analysis

BaiZe Medical (02609.HK) is a Hong Kong-listed company focusing on full-cycle oncology medical services, covering screening, diagnosis, treatment, and rehabilitation [0]. The company was listed on June 23, 2025, with an IPO price of HK$4.22 and a first-day gain of 42.18% [0]. After listing, its stock price experienced significant fluctuations: it once surged to HK$17.06 in September due to inclusion in the Stock Connect and Hang Seng Index series [0], but fell to a three-month low of about HK$5.75 by November [0]. Market data shows that as of the analysis, the company’s market capitalization is approximately HK$7.581 billion, with a price-earnings ratio of -521.7, indicating a loss-making state [0]; its net loss in the 2025 interim report was HK$27.62 million, a year-on-year increase of 139.18% [0]. In terms of capital flow, Southbound funds reduced their positions by 802,800 shares on November 26, and reduced positions on 12 out of the past 20 trading days, with a cumulative net reduction of 1.8786 million shares [0].

Although BaiZe Medical is currently operating at a loss, the Chinese private oncology medical service market it is in has strong growth potential. It is expected that the market size will grow from RMB 53 billion to RMB 109.2 billion from 2022 to 2026, with a compound annual growth rate of 19.8% [0]. The company’s stock price fluctuations are significantly affected by policies and capital flows: inclusion in the Stock Connect and Hang Seng Index series once brought short-term catalysts, but the continuous reduction of positions by Southbound funds also puts pressure on the stock price. No clear recent catalyst (such as company announcements or major news events) was found for the company becoming a hot stock in Hong Kong stocks this time, which may be related to market sentiment fluctuations or overall sector momentum [0].

: The company is currently in a loss-making state, and the high negative price-earnings ratio reflects profit pressure [0]; continuous reduction of positions by Southbound funds may put further downward pressure on the stock price [0]; the oncology medical service market is highly competitive, and changes in industry regulatory policies may affect business development [0].

: The rapid growth of the Chinese private oncology medical service market provides broad development space for the company [0]; if the company can improve operational efficiency and expand business scale, it is expected to turn losses into profits [0].

As a hot stock in Hong Kong stocks, BaiZe Medical (02609.HK) has the growth attributes of the oncology medical service industry, but currently faces profit challenges and capital flow pressure. The increase in market attention to it lacks a clear catalyst, and the subsequent trend of its stock price may be jointly affected by the company’s operational improvement, industry policy changes, and capital flow.